Global Process Owner - Production Planning & Manufacturing Execution

Diabetic Foot Ulcer Treatment Market to grow at a CAGR of 7.01% from 2026 to 2034; rising incidence of DFUs is propelling Market Growth. September 04, 2026 | Healthcare The global diabetic foot ulcer treatment market size was valued at USD 7.14 billion in 2025. The market is expected to grow from USD 7.53 billion in 2026 to USD 12.46 billion by 2034, exhibiting a CAGR of 6.5% during the forecast period. Fortune Business Insights(TM) presents this information in its report titled "Diabetic Foot Ulcer Treatment Market Size, Share & Industry Analysis, By Ulcer Type (Neuropathic Ulcers, Ischemic Ulcers, and Neuro-Ischemic Ulcers), By Product (Wound-Care Dressings [Antimicrobial Dressings, Foam Dressings, and Hydrogel Dressings], Wound-Care Devices [Negative Pressure Wound Therapy, Ultrasound Therapy, and Hyperbaric Oxygen Therapy], and Active Therapies [Skin Grafts & Substitutes and Growth Factors]), By Severity (Mild, Moderate, and Severe), By End User (Hospitals, Clinics, Ambulatory Surgical Centers, Homecare Settings, and Others), and Regional Forecast, 2026-2034". Diabetic Foot Ulcers (DFUs) are chronic wounds that affect individuals with both type 1 and type 2 diabetes. They represent a serious complication of diabetes and are generally characterized by wounds on the feet that heal slowly or fail to heal completely. Without timely and effective treatment, DFUs may progress to severe infections and, in advanced cases, result in lower-limb amputation. DFU care encompasses a broad spectrum of treatment products and therapies designed to promote wound healing, prevent infection, and reduce ulcer-related complications. These include advanced wound dressings such as antimicrobial & hydrogel dressings and devices such as negative pressure wound therapy (NPWT), Hyperbaric Oxygen Therapy (HBOT), and active therapies such as skin graft substitutes. Offloading devices are also widely used to minimize pressure on affected areas and support healing. The rising prevalence of DFUs among the growing diabetic population is expected to increase demand for these treatment solutions, thereby supporting market expansion. Convatec Announced Completion of a Significant Multi-year Expansion at Its Rhymney Production Unit In July 2026, Convatec, a renowned medical product and technology company specializing in solutions for the management of chronic conditions, announced the successful completion of a multi-year expansion project at its manufacturing facility in Rhymney, South Wales. The company invested more than USD 27.1 million in the expansion, aimed at strengthening the site's manufacturing capabilities and supporting the growing demand for advanced healthcare products. Growing Prevalence of Diabetes Fosters Market Growth The mounting diabetes burden globally is a primary factor driving the increasing incidence of diabetic foot ulcers, one of the most serious complications associated with the disease. The expanding geriatric population, sedentary lifestyles, dietary changes, and rising obesity rates are contributing to the global diabetes burden. Moreover, clinical evidence indicates that individuals with diabetes are substantially more likely to develop foot ulcers than non-diabetic individuals, further intensifying the need for effective treatment options. For instance, an article published in the International Wound Journal in 2023 reported that diabetic foot ulcers have a global prevalence of approximately 6.3% based on available studies assessing their global epidemiology. Technological innovations in diabetic foot ulcer treatment management are encouraging the development and uptake of smart wound dressings. Leading companies are increasing their investments in R&D to introduce innovative products with enhanced monitoring and healing capabilities, thereby supporting the global diabetic foot ulcer treatment market growth. On the other hand, the low rates of wound diagnosis and treatment across emerging countries are impeding diabetic foot ulcer treatment demand. Major Players Emphasize Product Portfolio Expansion to Support Their Dominance Leading diabetic foot ulcer treatment companies are maintaining their market dominance through broad product portfolios, strategic acquisitions, collaborations, and other inorganic growth initiatives implemented across various regions. Smith+Nephew and Solventum hold prominent positions in the market, driven by their extensive offerings and strong global footprint. In addition, the rising emphasis on R&D is encouraging companies to launch technologically advanced and differentiated wound care products, thereby strengthening their market presence. * In April 2024, Smith+Nephew introduced its RENASYS EDGE Negative Pressure Wound Therapy (NPWT) System in the U.S., providing a patient-focused option for managing chronic wounds. List of Key Players Mentioned in the Report * Coloplast A/S (Denmark) * Smith+Nephew (U.K.) * Solventum (U.S.) * Convatec Inc. (U.K.) * Integra LifeSciences (U.S.) * Braun SE (Germany) * Cardinal Health (U.S.) * Mölnlycke Health Care AB (Sweden) * Essity Aktiebolag (publ). (Sweden) * MIMEDX Group, Inc. (U.S.) Key Industry Development * April 2024: Smith+Nephew reported that the U.K. National Institute for Health and Care Excellence (NICE) reviewed its PICO Single Use Negative Pressure Wound Therapy System (sNPWT). NICE concluded that the system delivers improved clinical outcomes compared with standard dressings in decreasing the risk of surgical site infections. Further Report Findings * North America maintained its position as the leading regional market, reaching USD 2.65 billion in 2024 and increasing to USD 2.78 billion in 2025. The widespread adoption of advanced wound-care products, well-developed hospital infrastructure, and rising healthcare expenditure supports the region's strong market position. * Europe is predicted to expand at a CAGR of 6.2% over the forecast period, representing the second-fastest growth among regions, and is projected to reach USD 2.05 billion in 2026. Increasing diabetic population, combined with the region's advanced healthcare infrastructure, is anticipated to accelerate market expansion. * Based on ulcer type, neuro-ischemic ulcers accounted for the largest diabetic foot ulcer treatment market share in 2025. The rising incidence of neuro-ischemic ulcers among diabetic patients is increasing the need for specialized treatment solutions. Furthermore, the introduction of innovative wound-care products, skin substitutes, and NPWT technologies by prominent companies is likely to create additional growth opportunities for this segment. * By product, wound-care dressings led the market in 2025 due to their effectiveness and versatility in managing DFUs. Leading producers are intensifying R&D efforts to develop more advanced dressing technologies, providing further momentum to the segment. Table of Segmentation | ATTRIBUTE | DETAILS | | Study Period | 2021-2034 | | Base Year | 2025 | | Estimated Year | 2026 | | Forecast Period | 2026-2034 | | Historical Period | 2021-2024 | | Unit | Value (USD billion) | | Growth Rate | CAGR of 6.5% from 2026 to 2034 | | Segmentation | By Ulcer Type, Product, Severity, End User, and Region | | By Ulcer Type | * Neuropathic Ulcers * Ischemic Ulcers * Neuro-ischemic Ulcers | | By Product | * Wound-care Dressings * Antimicrobial Dressings * Foam Dressings * Film Dressings * Alginate Dressings * Hydrogel Dressings * Other Dressings * Wound-care Devices * Negative Pressure Wound Therapy (NPWT) * Ultrasound Therapy * Hyperbaric Oxygen Therapy (HBOT) * Others * Active Therapies * Skin Grafts & Substitutes * Growth Factors * Others * Others | | By Severity | * Mild * Moderate * Severe | | By End User | * Hospitals * Clinics * Ambulatory Surgical Centers * Homecare Settings | | By Region | * North America (By Ulcer Type, By Product, By Severity, By End User, and By Country) * U.S. * Canada * Europe (By Ulcer Type, By Product, By Severity, By End User, and By Country/Sub-Region) * U.K. * Germany * France * Spain * Italy * Scandinavia * Rest of Europe * Asia Pacific (By Ulcer Type, By Product, By Severity, By End User, and By Country/Sub-Region) * Japan * China * India * Australia * Southeast Asia * Rest of Asia Pacific * Latin America (By Ulcer Type, By Product, By Severity, By End User, and By Country/Sub-Region) * Brazil * Mexico * Rest of Latin America * Middle East & Africa (By Ulcer Type, By Product, By Severity, By End User, and By Country/Sub-Region) * GCC * South Africa * Rest of Middle East & Africa | * PDF * 2025 * 2021 - 2024 * 160 Choose license Type * 4850 5850 6850.

Convatec reiterates guidance, unveils $200m buyback after US setback. Convatec Group Plc (LON: CTEC), the FTSE 100 medical products group focused on chronic-condition care, reported interim revenue up 4.4% to $1,232m for the six months to June, with organic growth of 5.0% excluding its InnovaMatrix wound-care product, in line with its target range. Convatec shares closed at 225.4p on Monday, unchanged on the day, against a 52-week range of 193p to 255.6p. Price at open this morning is 226.4. The headline growth conceals a near-total collapse in InnovaMatrix, a skin-substitute product used in wound care, after the US Centers for Medicare and Medicaid Services cut its Medicare reimbursement rate by more than 85% from 1 January. Revenue from the product fell by more than 90% from $39m in H1 2025, forcing a $69m non-cash impairment. That impairment drove reported operating profit down 36.1% to $115m, and cut reported operating margin to 9.3% from 15.2% a year earlier. On the adjusted basis management uses to guide the market, the picture is steadier: adjusted operating margin held at 21.2%, against 21.3% a year earlier, while adjusted diluted earnings per share rose 6.3% to 8.5 cents. Reported diluted EPS, by contrast, fell to 2.7 cents from 5.1 cents. Convatec narrowed its full-year organic growth guidance, excluding InnovaMatrix, to 5.5-6.5%, kept its adjusted margin target above 23%, and reiterated double-digit adjusted EPS growth. Chief executive Jonny Mason said: "Convatec delivered further broad-based and resilient growth across our chronic care categories. We are on track for another year of margin expansion and double-digit EPS growth." The company also announced a new $200m share buyback, on top of the $300m completed in 2025, taking cumulative repurchases to $500m across the two years, alongside a 15% increase in the interim dividend. Net debt rose to $1,534m, taking net debt to adjusted EBITDA to 2.3 times from 1.9 times a year earlier, with management targeting around 2.0 times by year-end. Free cash flow to equity before growth spending fell to $22m from $98m, which Convatec attributed to normal seasonal working-capital swings it expects to reverse in the second half. Team Member The AskTraders Analyst Team features experts in technical and fundamental analysis, as well as traders specializing in stocks, forex, and cryptocurrency.

ConvaTec Group H1 earnings call highlights. August 4, 2026 Key points. * ConvaTec maintained its 2026 targets after delivering 5% first-half organic revenue growth excluding InnovaMatrix, 6% adjusted EPS growth and a 21.2% operating margin. Management expects stronger second-half growth, particularly in Infusion Care, and reaffirmed double-digit full-year EPS growth. * InnovaMatrix remains a significant headwind: first-half sales dropped to £2.5 million, prompting a £69 million non-cash impairment charge and reducing full-year revenue expectations to £5 million-£10 million. The company expects the product to approach breakeven in the second half as U.S. market conditions stabilize. * Shareholder returns and future investment increased: ConvaTec raised its interim dividend by 15% and launched a £200 million share buyback, while investing about $90 million in 2026 growth capital - primarily to expand Infusion Care capacity and support its product pipeline. * Interested in ConvaTec Group? Here are five stocks we like better. ConvaTec Group LON: CTEC said it remained on track to meet its 2026 financial targets after reporting 5% organic revenue growth in the first half, excluding the impact of its InnovaMatrix skin-substitute product. The company said revenue growth was broad-based across its four chronic-care categories, while it continued to invest in manufacturing capacity, new-product launches, simplification programs and technology. Management reiterated its expectation that growth will accelerate in the second half, led principally by Infusion Care. First-half operating margin was 21.2%, down 10 basis points from a year earlier but up 50 basis points at constant currency. Adjusted earnings per share rose 6%, with the company maintaining its expectation for double-digit EPS growth for the full year. Chief Financial Officer Fiona Ryder said ConvaTec expects around 100% free-cash-flow-to-equity conversion for 2026 despite lower first-half cash flow, which reflected working-capital timing and growth capital expenditures. The company increased its interim dividend by 15% and announced a £200 million share buyback program to be completed by year-end. InnovaMatrix creates revenue and margin headwind. InnovaMatrix sales fell £37 million year over year to £2.5 million in the first half, creating a little more than a 3% headwind to group revenue growth. ConvaTec now expects InnovaMatrix revenue of £5 million to £10 million for the full year, compared with previous expectations, representing an estimated 2.5% headwind to annual group revenue growth. The company took a £69 million non-cash impairment charge related to the product. Ryder said the reduction in expected InnovaMatrix revenue would not have a material negative impact on results beyond 2026. Management attributed the weak performance to uncertainty in the U.S. skin-substitutes market, including lower prices set by the Centers for Medicare & Medicaid Services, litigation challenging those actions and audit activity that has reduced physician activity. The company said InnovaMatrix sales began to improve in May and June versus earlier in the year, though the recovery has been slower than expected. Management said InnovaMatrix did not make money in the first half, but it expects the business to be close to breakeven in the second half. The company said roughly $10 million in sales would be required for the product to reach breakeven on an ongoing basis. * Advanced Wound Care: Revenue rose 3.4% excluding InnovaMatrix. Management said wound-care markets were somewhat softer than in 2025, while May and June were affected by order phasing for Aquacel. It still expects mid-single-digit growth for the category in 2026, supported by the continued rollout of ConvaFoam. * Ostomy Care: Organic growth was 4.3%. Esteem Body, the company's one-piece soft convex pouch, was annualizing at about $60 million in revenue and continuing to gain share. ESENTA accessories represented 20% of Ostomy Care sales. Flexi-Seal sales declined 4%, which management attributed to fewer intensive-care procedures during a less severe flu season. * Continence Care: Organic revenue grew 5.9%, driven by U.S. volume gains, international expansion and demand for hydrophilic products. GentleCath Air for Women more than doubled year over year and contributed one percentage point to category growth. * Infusion Care: Organic growth reached 7.4%, supported by diabetes demand and high-double-digit growth in therapies outside diabetes, including infusion sets used with AbbVie's Parkinson's disease treatment. Management expects double-digit Infusion Care growth in the second half and high-single-digit growth for the full year. Management said it has purchase orders supporting its expectation for stronger second-half Infusion Care growth and does not need newly added capacity to meet that near-term demand. Most of the larger capacity expansion is expected to come online in 2027 and later. Margin improvement expected in second half. ConvaTec reaffirmed guidance for an operating margin of at least 23% in 2026, despite an expected full-year InnovaMatrix drag of about 80 basis points and a foreign-exchange headwind of about 40 basis points. Discover more Cryptocurrency News Stock Split Calculator Ryder said the company expects a substantial second-half margin improvement due to higher seasonal revenue, four additional trading days in the second half, a more favorable Infusion Care sales mix, a lower InnovaMatrix impact and continuing productivity initiatives. These measures include manufacturing automation, strategic sourcing, debottlenecking, organizational simplification and reduced commercial and general-and-administrative expenses. The company said it expects operating margin to reach about 25% in the second half and remain in the mid-20% range from 2027. Management also noted that the legacy Bristol Myers Squibb amortization charge ended in July, reducing the gap between ConvaTec's reported and adjusted financial results going forward. Investment supports product pipeline and future growth. ConvaTec is investing about $90 million in growth capital expenditures during 2026, with the largest share directed toward Infusion Care capacity. It is also investing in manufacturing and launches across Wound Care, Ostomy Care and Continence Care. Management said capital expenditure is currently elevated as it adjusts to a higher growth trajectory, but expects it to settle at 5% to 7% of sales over time. The company highlighted its pipeline of "Wave Two" products, including ConvaNiox, ConvaFiber, ConvaVAC, Cure Aqua, GentleCath Air Pocket and Set, and Natura Body. ConvaNiox, a wound dressing initially focused on diabetic foot ulcers, is in limited market release and evaluation. Management said its first randomized controlled trial showed 60% more ulcers healed within 12 weeks and wound-area reduction three times faster than standard care. ConvaTec expects ConvaNiox to begin contributing meaningfully from 2028 rather than 2026 or 2027. It also said Flexi-Seal Air's launch has been delayed into 2027 to accommodate product-design refinements following customer evaluations. Management confirmed its medium-term objective of 6% to 8% annual organic revenue growth from 2027, supported by product launches, market-share gains and double-digit Infusion Care growth. It also expects continued double-digit EPS growth and leverage of about two times EBITDA at the end of 2026, including the newly announced share repurchase program. About ConvaTec Group (LON:CTEC). ConvaTec Group PLC engages in the development, manufacturing, and sale of medical products, services, and technologies in Europe, North America, and internationally. The company offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, and bladder cancer. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider ConvaTec Group, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ConvaTec Group wasn't on the list. While ConvaTec Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.